Amivantamab in NSCLC: Interpreting MARIPOSA and Guideline Placement

This discussion explores amivantamab’s unique mechanism of action and its role in the evolving treatment landscape of non–small cell lung cancer (NSCLC). Unlike traditional EGFR tyrosine kinase inhibitors, amivantamab is a bispecific antibody targeting both EGFR and MET, offering a differentiated approach to pathway inhibition. Panelists will review what the MARIPOSA trial demonstrated when comparing amivantamab-based therapy with osimertinib, focusing on key clinical outcomes and how these results may influence frontline treatment strategies for EGFR-mutated NSCLC. The conversation will also address how these data are reflected in current NCCN recommendations, including appropriate patient selection and positioning of amivantamab within the treatment algorithm.